An Extension Clinical Study of BCD-148 for the Treatment of Patients With PNH Previously Treated in Clinical Study No. BCD-148-2/NOCTURN
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Eculizumab
Related studies linked through entity extraction aliases.
Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG
- Status
- COMPLETED
- Phase
- PHASE3
Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Complement C5 mAb in the Treatment of Anti-GBM Disease
- Status
- COMPLETED
- Phase
- PHASE2
Eculizumab for Prevention of Antibody-Mediated Rejection in ABO-Incompatible Living Donor Kidney Transplantation
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China
- Status
- COMPLETED
- Phase
- PHASE3
Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China
- Status
- COMPLETED
- Phase
- PHASE3
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria
- Status
- TERMINATED
- Phase
- PHASE3
BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy
- Status
- TERMINATED
- Phase
- PHASE2
Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx
- Status
- COMPLETED
- Phase
- PHASE3
COVID-19 Soliris Expanded Access Protocol
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome
- Status
- COMPLETED
- Phase
- PHASE3
Complement Regulation to Undo Systemic Harm in Preeclampsia
- Status
- TERMINATED
- Phase
- PHASE2
A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Status
- TERMINATED
- Phase
- PHASE2
Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment
- Status
- COMPLETED
- Phase
- PHASE3
A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort
- Status
- UNKNOWN
- Phase
- PHASE2